Trial Profile

A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 12 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Islatravir (Primary)
Indications HIV-1 infections
Focus Adverse reactions; Therapeutic Use
Acronyms IMPOWER 22
Sponsors Merck & Co; Merck Sharp & Dohme

16 Oct 2023 Planned End Date changed from 22 Aug 2024 to 1 Jul 2024.
19 Jul 2023 Planned End Date changed from 5 Jul 2024 to 22 Aug 2024.
19 Jul 2023 Planned primary completion date changed from 5 Jul 2024 to 31 Jul 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com